Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 288-292

  Hurley, M N ^a,c   Ariff, A H Amin ^b   Bertenshaw, C ^c   Bhatt, J ^c   Smyth, A R ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Antibiotic; Cystic fibrosis; Pseudomonas; Susceptibility testing

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; MEROPENEM; PIPTAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BODY MASS; CYSTIC FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

ADOLESCENT; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862501656     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.02.006     Document Type: Article

References (18)

1. Hurley M.N., Amin Ariff AH, Smyth A. An audit of the investigation, antibiotic management and clinical outcome of pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros 2011, 10(Supplement 1):S25.
2. Cystic Fibrosis Foundation Patient Registry. 2008 Annual Data Report 2008, Cystic Fibrosis Foundation.
3. Douglas T.A., Brennan S., Gard S., Berry L., Gangell C., Stick S.M., et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009, 33(2):305-311.
4. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009, (Issue 4). [Art. No. CD004197]. 10.1002/14651858.CD004197.pub3.
5. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
6. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34(2):91-100.
7. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180(9):802-808.
8. Aaron S.D., Ferris W., Ramotar K., Vandemheen K., Chan F., Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002, 40(11):4172-4179.
9. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Chest 2003, 123(5):1495-1502.
10. Etherington C., Hall M., Conway S., Peckham D., Denton M. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Antimicrob Chemother 2008, 61(2):425-427.
11. Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group Laboratory standards for processing microbiological samples from people with cystic fibrosis 2010, Cystic Fibrosis Trust.
12. Lee T.W.R., Brownlee K.G., Denton M., Littlewood J.M., Conway S.P. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004, 37(2):104-110.
13. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing 2011.
14. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005, 366(9484):463-471.
15. Moskowitz S.M., Foster J.M., Emerson J.C., Gibson R.L., Burns J.L. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 2005, 56(5):879-886.
16. Marshall B.C. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!. Am J Respir Crit Care Med 2004, 169(7):781-782.
17. Plummer A., Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2011, (1):CD006682.
18. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182(5):627-632.